Key findings were further assessed through internal validation in an independent cohort of tofacitinib-treated RA patients and external validation using publicly available datasets.<h4>Results</h4>Multi-omics analyses revealed upregulation of ribosomal proteins in PBMCs of responders, with <i>RPL21</i> emerging as a potential immune-related candidate. This evidence concerns the gene RPL21 and rheumatoid arthritis.